Insights

article

Significant changes have taken place in the life sciences industry over the past few years. Since the Covid-19 pandemic, the U.S. government has urged biotech and pharmaceutical companies to increase domestic production in order to secure the drug su...

webinar

The webinar focuses on truncating drug development timelines in the aftermath of COVID-19. The featured speaker emphasizes phase-appropriate development, offering creative solutions and round-the-clock development across various continents.

webinar

This webinar will provide a general overview of mRNA therapeutics design and production and discuss the importance of robust quality systems in the context of GMP production of mRNA therapeutics.

webinar

To optimize manufacturing process performance and product quality, enhance supply chain reliability, and foster proactive continual improvement, the FDA’s Center for Drug Evaluation and Research (CDER) has established a program to promote quality m...

white paper

With experience in both chemistry and biologics, Curia is uniquely positioned to provide mRNA drug development solutions spanning discovery and engineering, mRNA drug substance formulation, and fill-finish and manufacturing of lipids and nucleosides.

white paper

Traditionally, early-stage and late-stage process development have been done separately, with early-stage mostly focused on material production and late-stage on process intensification. As more molecules in development fall under an orphan or fast-t...